{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T23:14:31Z","timestamp":1774394071078,"version":"3.50.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2017,4,11]],"date-time":"2017-04-11T00:00:00Z","timestamp":1491868800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2017,4,11]],"date-time":"2017-04-11T00:00:00Z","timestamp":1491868800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1007\/s10067-017-3627-4","type":"journal-article","created":{"date-parts":[[2017,4,11]],"date-time":"2017-04-11T10:54:39Z","timestamp":1491908079000},"page":"2063-2069","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Long-term efficacy and safety of golimumab in the treatment of multirefractory Beh\u00e7et\u2019s disease"],"prefix":"10.1007","volume":"36","author":[{"given":"Antonio","family":"Vitale","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giacomo","family":"Emmi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Lopalco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Fabiani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Gentileschi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Silvestri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Di Scala","family":"Gerardo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florenzo","family":"Iannone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno","family":"Frediani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mauro","family":"Galeazzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Lapadula","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donato","family":"Rigante","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7352-1275","authenticated-orcid":false,"given":"Luca","family":"Cantarini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,4,11]]},"reference":[{"key":"3627_CR1","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1111\/1346-8138.13381","volume":"43","author":"E Alpsoy","year":"2016","unstructured":"Alpsoy E (2016) Beh\u00e7et\u2019s disease: a comprehensive review with a focus on epidemiology, etiology and clinical features, and management of mucocutaneous lesions. J Dermatol 43:620\u2013632. doi:\n                    10.1111\/1346-8138.13381","journal-title":"J Dermatol"},{"key":"3627_CR2","doi-asserted-by":"publisher","first-page":"451675","DOI":"10.1155\/2015\/451675","volume":"2015","author":"C Rotondo","year":"2015","unstructured":"Rotondo C, Lopalco G, Iannone F et al (2015) Mucocutaneous involvement in Beh\u00e7et\u2019s disease: how systemic treatment has changed in the last decades and future perspectives. Mediat Inflamm 2015:451675. doi:\n                    10.1155\/2015\/451675","journal-title":"Mediat Inflamm"},{"key":"3627_CR3","first-page":"S3","volume":"33","author":"G Hatemi","year":"2015","unstructured":"Hatemi G, Seyahi E, Fresko I, Talarico R, Hamuryudan V (2015) Beh\u00e7et\u2019s syndrome: a critical digest of the 2014-2015 literature. Clin Exp Rheumatol 33:S3\u201314","journal-title":"Clin Exp Rheumatol"},{"key":"3627_CR4","first-page":"1078","volume":"335","author":"Criteria for diagnosis of Beh\u00e7et\u2019s disease","year":"1990","unstructured":"Criteria for diagnosis of Beh\u00e7et\u2019s disease (1990) International study Group for Beh\u00e7et\u2019s disease. Lancet 335:1078\u20131080","journal-title":"Lancet"},{"key":"3627_CR5","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1111\/jdv.12107","volume":"28","author":"International Team for the Revision of the International Criteria for Beh\u00e7et\u2019s Disease (ITR-ICBD)","year":"2014","unstructured":"International Team for the Revision of the International Criteria for Beh\u00e7et\u2019s Disease (ITR-ICBD) (2014) The international criteria for Beh\u00e7et\u2019s disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. J Eur Acad Dermatol Venereol 28:338\u2013347. doi:\n                    10.1111\/jdv.12107","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"3627_CR6","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1007\/s10067-006-0484-y","volume":"26","author":"FS Neves","year":"2007","unstructured":"Neves FS, Moraes JC, Kowalski SC, Goldenstein-Schainberg C, Lage LV, Gon\u00e7alves CR (2007) Cross-cultural adaptation of the Beh\u00e7et\u2019s disease Current activity Form (BDCAF) to Brazilian Portuguese language. Clin Rheumatol 26:1263\u20131267","journal-title":"Clin Rheumatol"},{"key":"3627_CR7","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1136\/ard.2007.080432","volume":"67","author":"G Hatemi","year":"2008","unstructured":"Hatemi G, Silman A, Bang D et al (2008) EULAR recommendations for the management of Beh\u00e7et disease. Ann Rheum Dis 67:1656\u20131662. doi:\n                    10.1136\/ard.2007.080432","journal-title":"Ann Rheum Dis"},{"key":"3627_CR8","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1159\/000358125","volume":"228","author":"A Vitale","year":"2014","unstructured":"Vitale A, Rigante D, Caso F et al (2014) Inhibition of interleukin-1 by canakinumab as a successful mono-drug strategy for the treatment of refractory Beh\u00e7et\u2019s disease: a case series. Dermatology 228:211\u2013214. doi:\n                    10.1159\/000358125","journal-title":"Dermatology"},{"key":"3627_CR9","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1007\/s10067-013-2443-8","volume":"34","author":"L Cantarini","year":"2015","unstructured":"Cantarini L, Vitale A, Scalini P et al (2015) Anakinra treatment in drug-resistant Behcet\u2019s disease: a case series. Clin Rheumatol 34:1293\u20131301. doi:\n                    10.1007\/s10067-013-2443-8","journal-title":"Clin Rheumatol"},{"key":"3627_CR10","doi-asserted-by":"publisher","first-page":"380","DOI":"10.3389\/fphar.2016.00380","volume":"7","author":"A Vitale","year":"2016","unstructured":"Vitale A, Insalaco A, Sfriso P et al (2016) A snapshot on the on-label and off-label use of the interleukin-1 inhibitors in Italy among rheumatologists and pediatric rheumatologists: a nationwide multi-center retrospective observational study. Front Pharmacol 7:380. doi:\n                    10.3389\/fphar.2016.00380","journal-title":"Front Pharmacol"},{"key":"3627_CR11","first-page":"238","volume":"18","author":"L Cantarini","year":"2016","unstructured":"Cantarini L, Stromillo ML, Vitale A et al (2016) Efficacy and safety of intravenous immunoglobulin treatment in refractory Behcet\u2019s disease with different organ involvement: a case series. Isr Med Assoc J 18:238\u2013242","journal-title":"Isr Med Assoc J"},{"key":"3627_CR12","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1080\/13543784.2016.1181751","volume":"25","author":"A Vitale","year":"2016","unstructured":"Vitale A, Rigante D, Lopalco G et al (2016) New therapeutic solutions for Beh\u00e7et\u2019s syndrome. Expert Opin Investig Drugs 25:827\u2013840. doi:\n                    10.1080\/13543784.2016.1181751","journal-title":"Expert Opin Investig Drugs"},{"key":"3627_CR13","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1007\/s10067-015-3004-0","volume":"35","author":"G Emmi","year":"2016","unstructured":"Emmi G, Talarico R, Lopalco G et al (2016) Efficacy and safety profile of anti-interleukin-1 treatment in Beh\u00e7et\u2019s disease: a multicenter retrospective study. Clin Rheumatol 35:1281\u20131286. doi:\n                    10.1007\/s10067-015-3004-0","journal-title":"Clin Rheumatol"},{"key":"3627_CR14","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s10067-016-3506-4","volume":"36","author":"C Fabiani","year":"2017","unstructured":"Fabiani C, Vitale A, Emmi G et al (2017) Interleukin (IL)-1 inhibition with anakinra and canakinumab in Beh\u00e7et\u2019s disease-related uveitis: a multicenter retrospective observational study. Clin Rheumatol 36:191\u2013197. doi:\n                    10.1007\/s10067-016-3506-4","journal-title":"Clin Rheumatol"},{"key":"3627_CR15","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.jaut.2015.06.005","volume":"62","author":"H Vallet","year":"2015","unstructured":"Vallet H, Riviere S, Sanna A et al (2015) Efficacy of anti-TNF alpha in severe and\/or refractory Beh\u00e7et\u2019s disease: multicenter study of 124 patients. J Autoimmun 62:67\u201374. doi:\n                    10.1016\/j.jaut.2015.06.005","journal-title":"J Autoimmun"},{"key":"3627_CR16","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s10067-016-3480-x","volume":"36","author":"C Fabiani","year":"2017","unstructured":"Fabiani C, Vitale A, Emmi G et al (2017) Efficacy and safety of adalimumab in Beh\u00e7et\u2019s disease-related uveitis: a multicenter retrospective observational study. Clin Rheumatol 36:183\u2013189. doi:\n                    10.1007\/s10067-016-3480-x","journal-title":"Clin Rheumatol"},{"key":"3627_CR17","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1007\/s10067-016-3417-4","volume":"36","author":"A Vitale","year":"2017","unstructured":"Vitale A, Emmi G, Lopalco G et al (2017) Adalimumab effectiveness in Beh\u00e7et\u2019s disease: short and long-term data from a multicenter retrospective observational study. Clin Rheumatol 36:451\u2013455. doi:\n                    10.1007\/s10067-016-3417-4","journal-title":"Clin Rheumatol"},{"key":"3627_CR18","first-page":"98","volume":"32","author":"M Melikoglu","year":"2005","unstructured":"Melikoglu M, Fresko I, Mat C et al (2005) Short-term trial of etanercept in Beh\u00e7et\u2019s disease: a double blind, placebo controlled study. J Rheumatol 32:98\u2013105","journal-title":"J Rheumatol"},{"key":"3627_CR19","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1007\/s12013-014-9860-4","volume":"69","author":"D Ma","year":"2014","unstructured":"Ma D, Zhang CJ, Wang RP, Wang L, Yang H (2014) Etanercept in the treatment of intestinal Behcet\u2019s disease. Cell Biochem Biophys 69:735\u2013739. doi:\n                    10.1007\/s12013-014-9860-4","journal-title":"Cell Biochem Biophys"},{"key":"3627_CR20","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.clineuro.2006.11.002","volume":"109","author":"JE Alty","year":"2007","unstructured":"Alty JE, Monaghan TM, Bamford JM (2007) A patient with neuro-Beh\u00e7et\u2019s disease is successfully treated with etanercept: further evidence for the value of TNF alpha blockade. Clin Neurol Neurosurg 109:279\u2013281. doi:\n                    10.1016\/j.clineuro.2006.11.002","journal-title":"Clin Neurol Neurosurg"},{"key":"3627_CR21","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1177\/039463200902200235","volume":"22","author":"L Cantarini","year":"2009","unstructured":"Cantarini L, Tinazzi I, Caramaschi P, Bellisai F, Brogna A, Galeazzi M (2009) Safety and efficacy of etanercept in children with juvenile-onset Behcet\u2019s disease. Int J Immunopathol Pharmacol 22:551\u2013555. doi:\n                    10.1177\/039463200902200235","journal-title":"Int J Immunopathol Pharmacol"},{"key":"3627_CR22","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1007\/s00393-013-1307-6","volume":"73","author":"RH Mohammed","year":"2014","unstructured":"Mohammed RH (2014) Etanercept therapy in Beh\u00e7et\u2019s disease. The tight control strategy in refractory disease. Z Rheumatol 73:650\u2013656. doi:\n                    10.1007\/s00393-013-1307-6","journal-title":"Z Rheumatol"},{"key":"3627_CR23","doi-asserted-by":"publisher","first-page":"160","DOI":"10.3109\/09273948.2012.741744","volume":"21","author":"M Mesquida","year":"2013","unstructured":"Mesquida M, Victoria Hern\u00e1ndez M, Lloren\u00e7 V et al (2013) Beh\u00e7et disease-associated uveitis successfully treated with golimumab. Ocul Immunol Inflamm 21:160\u2013162. doi:\n                    10.3109\/09273948.2012.741744","journal-title":"Ocul Immunol Inflamm"},{"key":"3627_CR24","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1007\/s10067-014-2589-z","volume":"34","author":"L Cantarini","year":"2015","unstructured":"Cantarini L, Lopalco G, Vitale A et al (2015) Paradoxical mucocutaneous flare in a case of Beh\u00e7et\u2019s disease treated with tocilizumab. Clin Rheumatol 34:1141\u20131143. doi:\n                    10.1007\/s10067-014-2589-z","journal-title":"Clin Rheumatol"},{"key":"3627_CR25","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1007\/s10072-014-1820-7","volume":"35","author":"M Belluzzo","year":"2014","unstructured":"Belluzzo M, Dozzo M, Pigatto E, Schiavon F, Monti F (2014) A case of neuromyotonia in Beh\u00e7et disease during TNF-\u03b1 antagonist therapy. Neurol Sci 35:1637\u20131639. doi:\n                    10.1007\/s10072-014-1820-7","journal-title":"Neurol Sci"},{"key":"3627_CR26","first-page":"S34","volume":"34","author":"M Santos-G\u00f3mez","year":"2016","unstructured":"Santos-G\u00f3mez M, Calvo-R\u00edo V, Blanco R et al (2016) The effect of biologic therapy different from infliximab or adalimumab in patients with refractory uveitis due to Beh\u00e7et\u2019s disease: results of a multicentre open-label study. Clin Exp Rheumatol 34:S34\u2013S40","journal-title":"Clin Exp Rheumatol"},{"key":"3627_CR27","doi-asserted-by":"publisher","first-page":"717598","DOI":"10.1155\/2014\/717598","volume":"2014","author":"M Cordero-Coma","year":"2014","unstructured":"Cordero-Coma M, Calvo-R\u00edo V, Ad\u00e1n A et al (2014) Golimumab as rescue therapy for refractory immune-mediated uveitis: a three-center experience. Mediat Inflamm 2014:717598. doi:\n                    10.1155\/2014\/717598","journal-title":"Mediat Inflamm"},{"key":"3627_CR28","first-page":"S54","volume":"29","author":"I Olivieri","year":"2011","unstructured":"Olivieri I, Leccese P, D\u2019Angelo S et al (2011) Efficacy of adalimumab in patients with Beh\u00e7et\u2019s disease unsuccessfully treated with infliximab. Clin Exp Rheumatol 29:S54\u2013S57","journal-title":"Clin Exp Rheumatol"},{"key":"3627_CR29","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.1093\/rheumatology\/keu266","volume":"53","author":"V Calvo-R\u00edo","year":"2014","unstructured":"Calvo-R\u00edo V, Blanco R, Beltr\u00e1n E et al (2014) Anti-TNF-\u03b1 therapy in patients with refractory uveitis due to Beh\u00e7et\u2019s disease: a 1-year follow-up study of 124 patients. Rheumatology (Oxford) 53:2223\u20132231. doi:\n                    10.1093\/rheumatology\/keu266","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"3627_CR30","doi-asserted-by":"publisher","first-page":"940-948.e3","DOI":"10.1016\/j.cgh.2014.08.042","volume":"13","author":"Satoshi Tanida","year":"2015","unstructured":"Tanida S, Inoue N, Kobayashi K, et al (2015) Adalimumab for the treatment of Japanese patients with intestinal Beh\u00e7et\u2019s disease. Clin Gastroenterol Hepatol 13:940-8.e3. doi: \n                    10.1016\/j.cgh.2014.08.042\n                    \n                  .","journal-title":"Clinical Gastroenterology and Hepatology"},{"key":"3627_CR31","doi-asserted-by":"publisher","first-page":"e3863","DOI":"10.1097\/MD.0000000000003863","volume":"95","author":"T Hibi","year":"2016","unstructured":"Hibi T, Hirohata S, Kikuchi H et al (2016) Infliximab therapy for intestinal, neurological, and vascular involvement in Behcet disease: efficacy, safety, and pharmacokinetics in a multicenter, prospective, open-label, single-arm phase 3 study. Medicine (Baltimore) 95:e3863. doi:\n                    10.1097\/MD.0000000000003863","journal-title":"Medicine (Baltimore)"},{"key":"3627_CR32","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.semarthrit.2010.09.002","volume":"41","author":"A Arida","year":"2011","unstructured":"Arida A, Fragiadaki K, Giavri E, Sfikakis PP (2011) Anti-TNF agents for Beh\u00e7et\u2019s disease: analysis of published data on 369 patients. Semin Arthritis Rheum 41:61\u201370. doi:\n                    10.1016\/j.semarthrit.2010.09.002","journal-title":"Semin Arthritis Rheum"},{"key":"3627_CR33","doi-asserted-by":"publisher","first-page":"22","DOI":"10.2174\/1574886310666151014115401","volume":"11","author":"MM Luchetti","year":"2016","unstructured":"Luchetti MM, Balloni A, Gabrielli A (2016) Biologic therapy in inflammatory and Immunomediated arthritis: safety profile. Curr Drug Saf 11:22\u201334","journal-title":"Curr Drug Saf"}],"updated-by":[{"DOI":"10.1007\/s10067-018-4302-0","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2018,9,22]],"date-time":"2018-09-22T00:00:00Z","timestamp":1537574400000}}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-017-3627-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-017-3627-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-017-3627-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,17]],"date-time":"2020-09-17T08:56:38Z","timestamp":1600332998000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-017-3627-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,11]]},"references-count":33,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["3627"],"URL":"https:\/\/doi.org\/10.1007\/s10067-017-3627-4","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s10067-018-4302-0","asserted-by":"object"}]},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,11]]},"assertion":[{"value":"28 March 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2018","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"In the original version of this article the author name Gerardo Di Scala was originally presented incorrectly as \u2018Di Scala Gerardo\u2019; this has been corrected in this article.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2018","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"In the original version of this article the author name Gerardo Di Scala was originally presented incorrectly as ?Di Scala Gerardo?; this has been corrected in this article.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}